Literature DB >> 29038648

Overview of Therapeutic Drug Monitoring of Biologic Agents in Patients With Inflammatory Bowel Disease.

Adam Cheifetz1.   

Abstract

Entities:  

Year:  2017        PMID： 29038648      PMCID： PMC5635433     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  12 in total

1.  Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.

Authors:  Namita Singh; Casey J Rosenthal; Gil Y Melmed; James Mirocha; Sharmayne Farrior; Silvia Callejas; Bhavna Tripuraneni; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

2.  Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Authors:  Henit Yanai; Lev Lichtenstein; Amit Assa; Yoav Mazor; Batia Weiss; Arie Levine; Yulia Ron; Uri Kopylov; Yoram Bujanover; Yoram Rosenbach; Bella Ungar; Rami Eliakim; Yehuda Chowers; Raanan Shamir; Gerald Fraser; Iris Dotan; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-25       Impact factor: 11.382

Review 3.  Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy.

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Am J Gastroenterol       Date:  2017-02-21       Impact factor: 10.864

4.  Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Authors:  Konstantinos Papamichael; Filip Baert; Sophie Tops; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Ann Gils; Marc Ferrante
Journal:  J Crohns Colitis       Date:  2016-07-11       Impact factor: 9.071

5.  Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.

Authors:  Konstantinos Papamichael; Karen A Chachu; Ravy K Vajravelu; Byron P Vaughn; Josephine Ni; Mark T Osterman; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-30       Impact factor: 11.382

6.  A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.

Authors:  Fernando S Velayos; James G Kahn; William J Sandborn; Brian G Feagan
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

7.  Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Authors:  Gil Y Melmed; Peter M Irving; Jennifer Jones; Gilaad G Kaplan; Patricia L Kozuch; Fernando S Velayos; Leonard Baidoo; Miles P Sparrow; Brian Bressler; Adam S Cheifetz; Shane M Devlin; Laura E Raffals; Niels Vande Casteele; Diane R Mould; Jean-Fred Colombel; Marla Dubinsky; William J Sandborn; Corey A Siegel
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-14       Impact factor: 11.382

8.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.

Authors:  Casper Steenholdt; Jørn Brynskov; Ole Østergaard Thomsen; Lars Kristian Munck; Jan Fallingborg; Lisbet Ambrosius Christensen; Gitte Pedersen; Jens Kjeldsen; Bent Ascanius Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark Andrew Ainsworth
Journal:  Gut       Date:  2013-07-22       Impact factor: 23.059

9.  Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.

Authors:  Byron P Vaughn; Manuel Martinez-Vazquez; Vilas R Patwardhan; Alan C Moss; William J Sandborn; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325

Review 10.  Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.

Authors:  R Khanna; B D Sattin; W Afif; E I Benchimol; E-J Bernard; A Bitton; B Bressler; R N Fedorak; S Ghosh; G R Greenberg; J K Marshall; R Panaccione; E G Seidman; M S Silverberg; A H Steinhart; R Sy; G Van Assche; T D Walters; W J Sandborn; B G Feagan
Journal:  Aliment Pharmacol Ther       Date:  2013-07-14       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.